Home > News > pSivida cancer cure ready for human testing
April 6th, 2004
pSivida cancer cure ready for human testing
Abstract:
pSivida Limited (PSD) today announced that its Singaporean subsidiary, pSiOncology Pte Ltd has successfully completed a final pre-clinical study for its lead BioSiliconTM product, BrachySilTM. This important and final pre-clinical milestone now paves the way for a ‘first in man’ evaluation of both BioSilicon and BrachySil, they announced. BrachySil is the Company’s lead product and is targeted to the substantial brachytherapy market, which is currently worth $600 million and expected to exceed US$1 billion by 2005.
Source:
egoli
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Announcements
Rice membrane extracts lithium from brines with greater speed, less waste October 3rd, 2025
Researchers develop molecular qubits that communicate at telecom frequencies October 3rd, 2025
Next-generation quantum communication October 3rd, 2025
"Nanoreactor" cage uses visible light for catalytic and ultra-selective cross-cycloadditions October 3rd, 2025
|
|
||
|
|
||
| The latest news from around the world, FREE | ||
|
|
||
|
|
||
| Premium Products | ||
|
|
||
|
Only the news you want to read!
Learn More |
||
|
|
||
|
Full-service, expert consulting
Learn More |
||
|
|
||